Clinical trial / 2012
Zinc adjunct therapy significantly reduced case fatality in children with severe pneumonia, with a greater reduction seen in HIV-infected children.
In this trial, 352 children aged 6 to 59 months with severe pneumonia were randomized to daily zinc (10 mg or 20 mg based on age) or placebo for 7 days alongside standard antibiotics. Time to normalization of respiratory rate, temperature, and oxygen saturation did not differ significantly between groups. However, case fatality was significantly lower in the zinc group (4.0%, 7/176) compared to placebo (11.9%, 21/176; RR 0.33, 95% CI 0.15 to 0.76). The absolute risk reduction was substantially greater in HIV-positive children (26 per 100) than in HIV-negative children (2 per 100; P = 0.006).
- Study type
- Double-blind, randomized, placebo-controlled trial
- Who was studied
- 352 children aged 6 to 59 months with severe pneumonia in Uganda
- What was measured
- Normalization of respiratory rate, temperature, oxygen saturation; case fatality
THE PAPER
Zinc adjunct therapy reduces case fatality in severe childhood pneumonia: a randomized double blind placebo-controlled trial.
Srinivasan MG, Ndeezi G, Mboijana CK, Kiguli S, Bimenya GS, Nankabirwa V, Tumwine JK. BMC Med, 2012.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.